InnoCan Pharma (HAM:IP40) Days Sales Outstanding: (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HAM:IP40 InnoCan Pharma Corp HAM:IP40
54 GF Score
Price €1.45
GF Value €7.18
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is InnoCan Pharma Days Sales Outstanding?

InnoCan Pharma's average Accounts Receivable for the three months ended in Jun. 2026 was €0.00 Mil. InnoCan Pharma's Revenue for the three months ended in Jun. 2026 was €4.52 Mil. Hence, InnoCan Pharma's Days Sales Outstanding for the three months ended in Jun. 2026 was 0.00.

The historical rank and industry rank for InnoCan Pharma's Days Sales Outstanding or its related term are showing as below:

During the past 8 years, InnoCan Pharma's highest Days Sales Outstanding was 109.50. The lowest was 0.20. And the median was 2.10.

HAM:IP40's Days Sales Outstanding is not ranked *
in the Consumer Packaged Goods industry.
Industry Median: 38.63
* Ranked among companies with meaningful Days Sales Outstanding only.

InnoCan Pharma's Days Sales Outstanding declined from Jun. 2025 (0.01) to Jun. 2026 ().

InnoCan Pharma  (HAM:IP40) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

InnoCan Pharma Days Sales Outstanding Related Terms

InnoCan Pharma Days Sales Outstanding Historical Data

* Premium members only.

The historical data trend for InnoCan Pharma's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

InnoCan Pharma Days Sales Outstanding Chart

InnoCan Pharma Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Days Sales Outstanding
Get a 7-Day Free Trial 3.60 2.11 0.43 0.21 -

InnoCan Pharma Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Days Sales Outstanding Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 - - - -

HAM:IP40 vs PG, CL, EL: Days Sales Outstanding Comparison

For the Household & Personal Products subindustry, InnoCan Pharma's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

InnoCan Pharma Days Sales Outstanding vs Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, InnoCan Pharma's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where InnoCan Pharma's Days Sales Outstanding falls into.


HAM:IP40
54GF Score
InnoCan Pharma Corp HAM:IP40
Days Sales Outstanding is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

InnoCan Pharma Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

InnoCan Pharma's Days Sales Outstanding for the fiscal year that ended in Dec. 2025 is calculated as

Days Sales Outstanding (A: Dec. 2025 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Dec. 2024 ) + Accounts Receivable (A: Dec. 2025 )) / count ) / Revenue (A: Dec. 2025 )*Days in Period
=( (0 + ) / 1 ) / 23.580116894978*365
=0 / 23.580116894978*365
=0.00

InnoCan Pharma's Days Sales Outstanding for the quarter that ended in Jun. 2026 is calculated as:

Days Sales Outstanding (Q: Jun. 2026 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Mar. 2026 ) + Accounts Receivable (A: Jun. 2026 )) / count ) / Revenue (A: Jun. 2026 )*Days in Period
=( ( + ) / 1 ) / 4.5153146349244*365 / 4
=0 / 4.5153146349244*365 / 4
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Is InnoCan Pharma (HAM:IP40) Overvalued in 2026?

Based on GuruFocus' analysis, InnoCan Pharma stock appears to be undervalued. The current stock price of €1.45 is trading 79.8% below its estimated GF Value™ of €7.18. GuruFocus considers InnoCan Pharma to be Possible Value Trap.

Key valuation signals for HAM:IP40:

  • Days Sales Outstanding:
  • GF Value™: €7.18 vs. price of €1.45 (79.8% below fair value)
  • GF Score™: 54/100 with 2 warning signs

No single metric tells the full story. See the HAM:IP40 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

InnoCan Pharma Business Description

Other Exchanges INNPF:USAINNO:Canada
Address 1015, 926 - 5 Avenue SW, Calgary, AB, CAN, T2P 0N7
InnoCan Pharma Corp is a Canadian pharmaceutical and consumer wellness company. It develops and sells cannabidiol-based cosmetic and self-care products, including anti-aging sleeping masks, eye serums, facial serums, and hair creams, marketed under its own brands and sold primarily through online marketplaces and e-commerce channels. The company also pursues pharmaceutical research, notably a preclinical cannabidiol-loaded liposome platform (CBD-LPT) intended for non-opioid pain management, developed through its subsidiary. Its operations are organized into online sales and other operations, with online sales generating the majority of revenue. The United States represents its largest market, though products are also sold internationally. Revenue is derived mainly from direct-to-consumer product sales, while the pharmaceutical program remains in development and does not yet contribute meaningful revenue.
54GF Score

Get the complete analysis for HAM:IP40

Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.45
Price
€7.18
GF Value